Premium
Cervix cancer. Treatment with combination vincristine and high doses of methotrexate
Author(s) -
Hakes Thomas,
Nikrui Majomosama,
Magill Gordon,
Ochoa Manuel
Publication year - 1979
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197902)43:2<459::aid-cncr2820430209>3.0.co;2-r
Subject(s) - medicine , methotrexate , cervix , vincristine , cancer , vulva , oncology , chemotherapy , surgery , cyclophosphamide
Patients with carcinoma of the cervix (31) and of the vulva (2) were treated with high doses of Methotrexate. The objective response rate was 17% with a median duration of 3 months. Three toxic deaths occurred. The response rate of high dose methotrexate in advanced and prior treated cervix cancer does not differ from that reported in prior studies with conventional doses of intravenous methotrexate. Cancer 43:459–464, 1979.